Ask AI
ProCE Banner Activity

Evolución de las terapias dirigidas en el linfoma difuso de células B grandes (LDCBG) recidivante/refractario

PDF

El panorama terapéutico para pacientes con LDCBG está evolucionando rápidamente, con varias terapias dirigidas en fase de desarrollo clínico. En este comentario, los expertos abordan cuestiones clave sobre el papel actual de la gemcitabina más el oxaliplatino en el LDCBG recidivante/refractario, el potencial curativo de las terapias con células CAR-T frente a los anticuerpos biespecíficos, y la selección y secuenciación de las terapias dirigidas tras la progresión con la terapia con células CAR-T en el tratamiento de pacientes con LDCBG recidivante/refractario.

Released: August 17, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with DLBCL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate colleagues and patients on the mechanisms of action and rationales for using novel targeted therapies in DLBCL

  • Evaluate the potential clinical application of emerging evidence for novel targeted therapies in DLBCL

  • Recommend the optimal targeted treatment for each patient with DLBCL, considering subtype, comorbidities, expert recommendations, and available evidence

  • Identify patients with DLBCL who are eligible for clinical trials evaluating novel targeted therapies

Financial Disclosures

Primary Author

Elizabeth Budde, MD, PhD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Crispr, Genentech/Roche; researcher: AstraZeneca, Merck.

Gilles Salles, MD, PhD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, BeOne, Bristol Myers Squibb, Daiichi Sankyo, Genentech/Roche, Genmab, GSK, Incyte, Ipsen, Janssen, Kite/Gilead, Lilly, Merck, Novartis; researcher (paid to institution): AbbVie, Daiichi Sankyo, Genentech, Genmab, Ipsen, Janssen.

Pier Luigi Zinzani, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Bristol Myers Squibb, Daichii Sankyo, Incyte, Janssen, Kite, Kyowa Kirin, Merck Sharp & Dohme, Novartis, Nurix, Roche, Sobi, Takeda.